Main > ONCOLOGY (**) > Lymphoma>NHL>B-Cell>FL *** > Treatment > Co: CH. R. ObinutuzuMAb+

---

Co: CH. R. ObinutuzuMAb+'s subsections
(*) EU Approval Date: 2016. 06.16
(*) USA Approval Date: 2016. 02.26
+Bendamustine
Company
Patent>Assignee; Claims; No.; Etc.
Patent>Total USA No.: 2
Patent>UpDate: 2017. 08.29
TradeMark (EU)
TradeMark (USA)
TradeMark (USA) Web-Site

Co: CH. R. ObinutuzuMAb+'s products
This section has no products